Sangamo Therapeutics Reports Q1 2024 Results

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results ... Announced discovery of novel next-generation ...

Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into ...

First Quarter Financial Performance. The first quarter of 2024 was challenging for Sangamo, with a reported consolidated net loss of $49.1 ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results ... By clicking “Accept All Cookies”, you agree to the storing of ...

Sangamo Therapeutics Announces Q1 2024 Financial Results and ...

Sangamo's operating expenses also decreased, with total operating expenses on a GAAP basis for the first quarter of 2024 being $52.0 million, ...

News Releases | Investor Relations - Sangamo Therapeutics, Inc.

(Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

RICHMOND, Calif., May 09, 2024--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS.

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results ; Total operating expenses. 38.8 ; Impairment of ...

Sangamo Therapeutics, Inc.: Overview

(Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics, Inc., a genomic medicine company, today reported business highlights and third quarter 2024 financial results.

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results ; Impairment of long-lived assets. 1,172.

Sangamo Therapeutics Announces First Quarter 2024 Conference ...

--(BUSINESS WIRE)--May 2, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has ...

Voyager Therapeutics Reports First Quarter 2024 Financial and ...

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results · $80 million of consideration up front and · $20 million for the purchase of ...

SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses ...

Sangamo Therapeutics (NASDAQ:SGMO) just reported results for the first quarter of 2024. Sangamo Therapeutics reported earnings per share of -27 ...

Sangamo Therapeutics, Inc. - BioSpace

Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms.

Sangamo Therapeutics (SGMO) Earnings Date and Reports 2024

Sangamo Therapeutics issued Q2 2024 earnings on August 6, 2024, reporting an EPS of -$0.17, which missed analysts' consensus estimates of -$0.16 by $0.01.

SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses ...

SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 · Sangamo Therapeutics reported earnings per share of -27 cents.

SGMO - Sangamo Therapeutics, Inc. Latest Stock News & Market ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has announced the release of its first quarter 2024 financial results on Thursday, May 9, 2024. The company will hold ...

Voyager Therapeutics Reports Second Quarter 2024 Financial and ...

R&D Expenses: Research and development expenses were $61.5 million for the six months ended June 30, 2024 , compared to $40.6 million for the same period in ...

Sangamo Therapeutics, Inc. Common Stock (SGMO) Earnings

Common Stock is expected* to report earnings on 11/12/2024 after market close. The report will be for the fiscal Quarter ending Sep 2024. According to Zacks ...

Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of ...

... first half of 2024. About the AFFINE study. The Phase 3 AFFINE ... results to differ materially from those expressed or implied by such statements ...